What is CNSY's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CNSY?

P/E (TTM) is n/a and 52-week range is $1.49 to $4.16 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CNSY figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CNSY?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-2.60B, EPS (TTM) near $-4.42 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Plus Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Austin, Texas, US, 6.9M shares outstanding, ISIN US72941H8060 when available from company profile and filing metadata.

Plus Therapeutics Inc

$CNSY

Health Care · Biotechnology

IR Run Scenarios

$1.93

+7.82%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 28 full-time employees. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Employees

Website

www.plustherapeutics.com/

IPO

2000-08-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)